Results from the BEST3 trial:
How effective is the Cytosponge test
in a primary care setting?
A series of online talks, conversations and Q&A sessions
The Cytosponge: detecting Barrett's oesophagus and aiming to prevent oesophageal cancer
The Cytosponge is a innovative test for patients with gastric reflux that makes it easier to identify whether a patient has Barrett's oesophagus, a condition that can develop into oesophageal cancer if not monitored or treated.
The Cytosponge can be swallowed by the patient and then drawn back out of the stomach on a string to collect cells from the oesophagus, which can then be checked for signs of Barrett's oeseophagus.
The BEST3 trial looked at whether this approach to identifying Barrett's oesophagus was effective when used in a primary care setting (that is, at a GP clinic).
You can read an easy-to-understand summary of the BEST3 trial and its results at the Cancer Research UK website here.
The teams associated with the BEST3 trial are planning a series of online sessions so you can learn more about the Cytosponge and what the BEST3 results mean for you.
The Cytosponge is a innovative test for patients with gastric reflux that makes it easier to identify whether a patient has Barrett's oesophagus, a condition that can develop into oesophageal cancer if not monitored or treated.
The Cytosponge can be swallowed by the patient and then drawn back out of the stomach on a string to collect cells from the oesophagus, which can then be checked for signs of Barrett's oeseophagus.
The BEST3 trial looked at whether this approach to identifying Barrett's oesophagus was effective when used in a primary care setting (that is, at a GP clinic).
You can read an easy-to-understand summary of the BEST3 trial and its results at the Cancer Research UK website here.
The teams associated with the BEST3 trial are planning a series of online sessions so you can learn more about the Cytosponge and what the BEST3 results mean for you.
[Illustration credit: Chris Madden for The Lancet]
